Adverse fetal outcomes: Expanding the role of infection (JAMA - Journal of the American Medical Association (2014) 311, 11 (1115-1116) DOI: 10.1001/jama.2014.1889)

摘要

The effects of endogenous matrix components on the quantification of therapeutics and biomarkers, and the impact of circulating therapeutics on the detection of ADAs varies significantly for each drug program. While often there are simple remedies to the interference, such as increasing the minimum required dilution or changing the sample dilution buffer, there are a handful of emerging technologies that have the potential to expand beyond the tradition remedies and reduce the impact of matrix interference in LBAs. The ETAPC and the Assay Inference team will continue to evaluate technologies that focus on improving drug tolerance and reducing matrix interferences. All ETAPC sub-teams are working together to draft a series of White Papers to provide recommendations on emerging technologies that would have a positive impact in the areas of assay sensitivity, real-time measurement, high-throughput and multiplexing, and assay interferences. The ETAPC welcomes any feedback with past or current experiences and evaluations on any of these areas.